logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Hemophilia B

    FiltersReset Filters
    3 results

    • alhemo

      (concizumab)
      Novo Nordisk
      Usage: Alhemo is indicated for routine prophylaxis to prevent or reduce bleeding episodes in adults and pediatric patients aged 12 and older with hemophilia A (factor VIII deficiency with inhibitors) and hemophilia B (factor IX deficiency with inhibitors).

    • feiba

      (anti-inhibitor coagulant complex)
      Takeda Pharmaceuticals America, Inc.
      Usage: FEIBA is indicated for hemophilia A and B patients with inhibitors for controlling and preventing bleeding episodes, perioperative management, and routine prophylaxis to reduce bleeding frequency. It is not for treating bleeding due to coagulation factor deficiencies without such inhibitors.

    • sevenfact

      (Coagulation Factor VIIa Recombinant Human)
      Laboratoire Français du Fractionnement et des Biotechnologies Société Anonyme (LFB S.A.)
      Usage: SEVENFACT (coagulation factor VIIa) is indicated for treating and controlling bleeding episodes in adults and adolescents (12 years and older) with hemophilia A or B who have inhibitors. It is not intended for patients with congenital Factor VII deficiency.